Revised: 20 August 2019

"In-loop" carbonylation—A simplified method for carbon-11 labelling of drugs and radioligands

Mélodie Ferrat¹ | Kenneth Dahl² | Christer Halldin¹ | Magnus Schou^{1,3}

¹Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden

²Centre for Addiction and Mental Health, CAMH & University of Toronto, Toronto, Canada

³AstraZeneca PET Science Centre, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

Correspondence

Mélodie Ferrat, Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Visionsgatan 70A, Psykforsknings centrum, Plan U1, 171 76 Stockholm, Sweden Email: melodie.ferrat@ki.se

Funding information

H2020 Marie Skłodowska-Curie Actions, Grant/Award Number: 675071; European Union's Horizon 2020, Grant/Award Number: 675071 Abstract

Transition-metal mediated carbonylation with ¹¹C-labelled carbon monoxide ([¹¹C]CO) is a versatile method for introducing ¹¹C ($t_{1/2}$ = 20.3 min) into drugs and radioligands for subsequent use in positron emission tomography (PET). The aim of the current study was to perform the ¹¹C-carbonylation reaction on the interior surface of a stainless-steel loop used for high performance liquid chromatography (HPLC). In the experimental setup, cyclotron produced ¹¹Clabelled carbon dioxide ($[^{11}C]CO_2$) was converted to $[^{11}C]CO$ by reduction over heated Molybdenum and swept into an HPLC loop pre-charged with the appropriate reaction mixture. Following a 5 min reaction, the radiochemical purity (RCP) and the trapping efficiency (TE) of the reaction mixture was determined. After optimization, [¹¹C]N-Benzylbenzamide was obtained in quantitative radiochemical yield (RCY) following a 5 min reaction at room temperature. The methodology was further applied to label [¹¹C]benzoic acid (RCP≥99%, TE>91%), [¹¹C]methyl benzoate (RCP≥99%, TE>93%) and [¹¹C] phthalide (RCP>99%, TE>88%). A set of pharmaceuticals was finally radiolabelled using non-optimized conditions. Excellent yields were obtained for the histamine-3 receptor radioligand [¹¹C]AZ13198083, the oncology drug [¹¹C]olaparib and the dopamine D2 receptor radioligand [¹¹C]raclopride, whereas a moderate yield was observed for the high-affinity dopamine D2 receptor radioligand [¹¹C]FLB457. The presented "in-loop" process proved efficient for diverse ¹¹C-carbonylations, providing [¹¹C]amides, [¹¹C]esters and ¹¹C]carboxylic acids in moderate to excellent RCYs. Based on the advantages associated with performing the radiolabelling step as an integrated part of the purification system, this methodology may become a valuable addition to the toolbox of methodologies used for ¹¹C-carbonylation of drugs and radioligands for PET.

KEYWORDS

carbon-11, 11C-carbonylation, loop, radioligands, radiopharmaceutical chemistry

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2019 The Authors. Journal of Labelled Compounds and Radiopharmaceuticals published by John Wiley & Sons Ltd

1 | INTRODUCTION

Positron emission tomography (PET) is a nuclear medicine imaging technique frequently used in translational research and drug development. After injection of a radiolabelled compound, PET produces a series of threedimensional images of the tracer tissue distribution inside the living organism. A fundamental pre-requisite for PET is that the tracer molecule is labelled with a positron emitting radionuclide, such as ¹¹C ($t_{1/2} = 20.3$ min). An important advantage with ¹¹C is that it can be introduced in the place of ¹²C in bio-organic compounds without any structural modification of the target compound.

Due to the short half-life of carbon-11, its radiochemistry needs to be rapid, efficient and preferably automated to minimize radiation exposure to the radiochemist. The radionuclide is commonly produced by a medical cyclotron in the form of $[^{11}C]$ methane or $[^{11}C]$ carbon dioxide. Because of the convenient conversion of these species into $[^{11}C]$ methyl iodide,^{1,2} the radionuclide is most commonly introduced into tracer molecules via ¹¹C-methylation. Although methyl groups are common in bioactive molecules, the majority lack this structural motif, which makes other labelling methods necessary to avoid structural modification of the tracer molecule.

Carbonyl groups are present in most biologically active molecules and are featured in a large number of drug molecules. Significant efforts have thus been put into the development of methods that use [¹¹C]carbon monox-ide ([¹¹C]CO), available in one step from [¹¹C]CO₂, to introduce the ¹¹C-carbonyl motif into tracer molecules. Radiochemistry with [¹¹C]CO is far from trivial, however, because of its low reactivity, poor solubility in organic solvents, high dilution in inert gas and the low concentration of isotopically labelled [¹¹C]CO.³ Many of these challenges have been successfully addressed via recirculating [¹¹C]CO through the reaction media,⁴ by performing the ¹¹C-carbonylation in a micro-autoclave (at 350 bar)^{3,5} or inside a microtube reactor.⁶ Other

fruitful methods for improving the yield for these reactions include chemical complexation of $[^{11}C]CO$ with diborane (BH₃- $[^{11}C]CO$),⁷ copper scorpionates (Cu-Sc- $[^{11}C]CO$),⁸ or introducing $[^{11}C]CO$ into the reaction media in a stream of Xenon carrier gas.⁹ These developments have resulted in numerous PET studies with tracer molecules labelled using palladium mediated ¹¹C-carbonylation chemistry.¹⁰⁻¹⁵

In an effort to simplify ¹¹C-carbonylation reactions from a technical perspective, we were inspired by previous work that employed captive solvents and reagents confined within plastic or stainless-steel tubes for the radiochemical synthesis.^{16,17} It was considered that such an approach, which maximizes the surface area between the gas and liquid phase, may be ideally suited for [¹¹C]CO radiochemistry because of the increased opportunity for the radioactive gas to equilibrate with solution. In addition, an approach in which the HPLC loop is the reaction vessel for the ¹¹C-carbonylation was considered ideal, since transfer losses in such case are minimized and process automation simplified according to Wilson et al.¹⁷ Thus, the aim of this study was to develop a novel "in-loop" method for PET tracer synthesis via 11 C-carbonylation using $[{}^{11}$ C]CO (Figure 1).

2 | RESULTS AND DISCUSSION

An initial requirement for most "in-loop" ¹¹C-labelling processes is that the product must be formed in a one-pot, one-step procedure. We thus started our investigation on the "in-loop" ¹¹C-aminocarbonylation of iodobenzene with benzylamine, forming the product [¹¹C]*N*-benzylbenzamide, a reaction that has been well characterized previously.¹⁸ DMF was first tested as a solvent for the reaction because of its captive properties and compatibility with "in-loop" ¹¹C-methylation.¹⁷ Likewise, the Pd-xantphos catalytic system was used as a starting point for the optimization, since it has been shown to



FIGURE 1 Schematic representation of the HPLC loop applied in the 11 C-carbonylation procedure. The yellow arrows indicate the flow direction for $[{}^{11}$ C]CO

102 WILEY Radiopharmaceuticals

be efficient in promoting ¹¹C-aminocarbonylation reactions.^{18,19} To our delight, a 5 min reaction at room temperature with Pd-xantphos in DMF furnished [¹¹C] *N*-benzylbenzamide at high trapping efficiency (TE), albeit at a moderate radiochemical purity (RCP) (Table 1, entry 1). Other solvents, such as DMSO and toluene, also provided good TEs in the "in-loop" ¹¹C-carbonylation (Table 1, entries 2 and 3), but the best yields were obtained in 1,4-dioxane and THF with near quantitative radiochemical yields (RCYs) (Table 1, entries 4 and 5). It is worth noting that an autoradiography experiment

TABLE 1 Investigation of solvent effects on the radiochemicalyield of $[^{11}C]N$ -benzylbenzamide

Entry	Solvent ^a	TE (%)	RCP (%)	RCY (%)
1	DMF	92	52	48
2	DMSO	95	88	84
3	Toluene	84	96	81
4	1,4-Dioxane	98	99 ± 0.5^{b}	97
5	THF	97	95 ± 5^{b}	92

Reaction conditions: $Pd_2(\pi\text{-cinnamyl})Cl_2$ (1 eq), Xantphos (2eq), lodobenzene(1,4 μ L), THF(700 μ L) in appropriate solvent (150 μ L) and Benzylamine (10 μ L)

^aOxidative addition takes place during evaporation of THF (700 μ L) ^bn = 2 (triplicate)

 ${}^{\mathrm{b}}n = 3$ (triplicate)

revealed that the majority of the radioactivity was trapped in the first quarter (~0.5 mL) of the stainless steel loop (Figure 2). In comparison, a control reaction with Pd (PPh₃)₄ provided [¹¹C]*N*-benzylbenzamide in 70% radiochemical purity, but with a poor TE (0.2%) and thus low RCY (0.14%).

With the improved conditions in hand, the methodology was next applied to radiolabel functional groups other than amides. Thus, a lactone, an ester and a carboxylic acid, were each radiolabelled with only minor modifications to those previously used in the radiosynthesis of $[^{11}C]N$ -benzylbenzamide (Scheme 1). Modifications to the original procedure include an increase in aryl halide concentration to improve trapping efficiency for $[^{11}C]$ phthalide, and an increased temperature to improve the RCP of $[^{11}C]methyl$ benzoate. The observed yields from these reactions are on par with those observed for reactions performed in either vial or in micro-reactor setups, thus demonstrating that the utility of the developed "in-loop" ¹¹C-carbonylation method extends beyond aminocarbonylation.^{18,20}

The "in-loop" carbonylation was finally tested on a set of drug-like molecules (Scheme 2). Thus, carbon-11 radiolabelling of the histamine type-3 receptor radioligand AZ13198083, the oncology drug olaparib and the dopamine D_2 receptor radioligands raclopride¹⁴





FIGURE 2 Picture (left) and autoradiographical image (right) of the HPLC loop following entrapment of $[^{11}C]CO$ in the synthesis of $[^{11}C]$ *N*-benzylbenzamide. The arrows indicate the entry and exit points of the He carrier gas through the HPLC loop



 $RCC \geq 99\%$; TE = 88%

[¹¹C]phtalide

 $[^{11}C]$ methylbenzoate RCC \geq 99% ; TE = 93%



 $[^{11}C]$ benzoic acid RCC $\geq 99\%$; TE = 91%

SCHEME 1 Synthesis of [¹¹C] phthalide, [¹¹C]methyl benzoate and [¹¹C] benzoic acid, via "in-loop" ¹¹C-carbonylation.



SCHEME 2 "In-loop" ¹¹C-carbonylation applied to four drug-like molecules.

and FLB457 were performed. Again, some modifications to the developed procedure were important to achieve good RCYs for these compounds. Most importantly, heating was required for all substrates to obtain the target tracers at high RCP. In addition, as was previously demonstrated by Skrydstrup et al., [¹¹C]olaparib cannot be produced with the Pd-xantphos system because of a phenyl scrambling from xantphos onto the aryl palladium complex.²¹ Instead, the Pd-^tBu₃ system was used to produce the target compound, thus demonstrating that other catalytic systems than the Pd-xantphos system are also compatible with the "in-loop" ¹¹C-carbonylation methodology. It is noteworthy that [¹¹C]FLB457 could only be produced at a moderate TE under the employed conditions, but this may well be improved

following further optimization. Finally, after integrating the loop system into a commercially available radiochemistry system (GE Tracerlab FX-C, Uppsala, Sweden), [¹¹C]AZ13198083 was obtained in a 38% decaycorrected RCY. The isolated radiochemical yield was lower than expected because of losses during HPLC isolation, formulation and sterile filtration. However, the RCP was >99% and the molar activity was 110 GBq/µmol.

103

3 | CONCLUSION

The presented "in-loop" process proved to be useful for diverse ¹¹C-carbonylation, providing both simple reference

-WILEY-Labelled Compounds and Radiopharmaceuticals

compounds (*e.g.* [¹¹C]amides, [¹¹C]esters and [¹¹C]carboxylic acids) as well as PET tracer molecules (*e.g.* [¹¹C] raclopride, [¹¹C]olaparib) in moderate to excellent RCYs. Given its simplicity and efficiency, the methodology has the potential to be widely implemented for carbonylations in PET tracer synthesis.

4 | MATERIALS AND METHODS

General experimental information

All chemical and solvents were obtained from Sigma-Aldrich (Sweden) and used without further purification, unless specified otherwise.

High performance liquid chromatography analysis (HPLC) was performed using a Hitachi L-6200 gradient pump and a Hitachi L-4000 variable wavelength UV-detector in a series with a Bioscan β +-flow detector. Analytical HPLC analysis was performed using a reverse phase column (XBridge, C18, 5 μ m, 4.6 x 150 mm):

- a-. [¹¹C]*N*-benzylbenzamide was eluted with a gradient between acetonitrile (A) and 0.1% TFA (B). The gradient was linear between 10 and 90% over 5 minutes and isocratic in between 5 and 8 min (ACN: 0.1% TFA, 90:10), at a flow rate of 3 ml/min.
- b-. [¹¹C]phthalide was eluted with a gradient between acetonitrile (A) and 0.1 M NH₄HCO₂ (B). The gradient was linear between 10 and 90% over 9 minutes and isocratic in between 9 and 10 min (ACN: 0.1 M NH₄HCO₂, 90:10), at a flow rate of 2 ml/min.
- c-. [¹¹C]methyl benzoate was eluted with a gradient between acetonitrile (A) and 0.1% TFA (B). The gradient was linear between 10 and 90% over 5 minutes and isocratic in between 5 and 0 min (ACN: 0.1% TFA, 90:10), at a flow rate of 3 ml/min.
- d-. [¹¹C]benzoic acid was eluted with a gradient between acetonitrile (A) and 0.1% TFA (B). The gradient was linear between 10 and 90% over 7 minutes and isocratic in between 7 and 10 min (ACN: 0.1% TFA, 90:10), at a flow rate of 3 ml/min.
- e-. [¹¹C]AZ13198083 was eluted with a gradient between acetonitrile (A) and 0.1 M NH₄HCO₂ (B). The gradient was linear between 10 and 90% over 9 minutes and isocratic in between 9 and 10 min (ACN: 0.1 M NH₄HCO₂, 90:10), at a flow rate of 2 ml/min.
- f-. [¹¹C]olaparib was eluted with a gradient between acetonitrile (A) and 0.01 M NH₄HCO₂ (B). The gradient was linear between 30 and 70% over 5 minutes and isocratic in between 5 and 6 min (ACN: 0.1 M NH₄HCO₂, 90:10), at a flow rate of 3 ml/min.
- g-. [¹¹C]raclopride was eluted with a gradient between acetonitrile (A) and 0.1% TFA (B). The gradient was linear between 10 and 90% over 9 minutes and

isocratic in between 9 and 10 min (ACN: 0.1% TFA, 90:10), at a flow rate of 2 ml/min.

h-. [¹¹C]FLB457 was eluted with a gradient between acetonitrile (A) and 0.1 M NH₄HCO₂ (B). The gradient was linear between 30 and 70% over 9 minutes and isocratic in between 9 and 10 min (ACN: 0.1 M NH₄HCO₂, 90:10), at a flow rate of 2 ml/min.

The identity of all radioactive products was confirmed by co-elution with the corresponding non-radioactive compound.

4.1 | Radiochemistry

All experiments were performed in accordance with local and national rules and laws that govern the work with open sources of radiation. The study was carried out at the PET Centre, Karolinska Institutet (Stockholm, Sweden).

¹¹CCC₂ was produced by a GEMS PETtrace cyclotron (General Electrics Medical Systems, Uppsala, Sweden). The ¹⁴N(p, α)¹¹C nuclear reaction, performed by proton bombardment of a pressurized gas target containing nitrogen (AGA, Nitrogen 6.0) and 1% oxygen (AGA, Oxygen 4.8), was used to produce $[^{11}C]CO_2$. At the end of bombardment (EOB), $[^{11}C]CO_2$ was transferred from the target to a [¹¹C]CO-synthesizer prototype (General Electrics Medical Systems, Uppsala, Sweden). [¹¹C]CO₂ was trapped on a molecular sieve column (0.6 mg packed in a 1/4" tube, mesh 80/100, GRACE, USA) at room temperature. The accumulated $[^{11}C]CO_2$ was released into a controlled stream of helium (10 ml/min) while heating the molecular sieve trap to 360°C. The purified $[^{11}C]CO_2$ was pre-concentrated by a stainless steel loop trap immersed in liquid nitrogen (-196°C) prior to on-line reduction over a heated Molybdenum column (850°C). The effluent gas was purified through an Ascarite® (sodium hydroxide-coated silica, 20-30 mesh, Sigma-Aldrich, Sweden) column prior to concentrating the ^{[11}C]CO on a silica gel trap immersed in liquid nitrogen. Following completed entrapment, [¹¹C]CO was released in a stream of Helium into a stainless steel HPLC loop for the ¹¹C-carbonylation reaction. Untrapped [¹¹C]CO was collected in a gas-tight bag (Tedlar® gas sampling bag push lock valve 1L, Sigma-Aldrich, Sweden).

4.2 | In-loop ¹¹C-carbonylation setup

A commercial HPLC injection valve (VICI, #C52-12061, Switzerland) was equipped with a stainless-steel loop (2 mL, VICI, #SL2KCUW, Switzerland) and an injection port (for 1/16" fill port, VICI #VISF-2, Switzerland). Prior to

<u>104</u>

start of synthesis, the injection valve was set to LOAD position (Figure 1) and a solution of aryl halide, palladiumsource, supporting ligand and nucleophile in anhydrous solvent, was injected using a 1 mL syringe capped with a filter (Acrodisc 13 mm minispike with 0.45 µm GHP Membrane, Sigma-Aldrich, Sweden) through the injection port of the loop. The isolated and concentrated [¹¹C]CO was then swept into the loop at 5 mL/min, and after a 5 min reaction, the contents of the loop were transferred to a sealed test tube by purging the loop with THF (~2 mL). After transfer to the test tube, the radioactivity in the test tube was measured before and after it was purged with N_2 (to assess TE), followed by a measurement of the gas waste bag that was connected on the outlet of the HPLC loop. The radioactivity in the test tube was also analyzed using radio-HPLC to assess the RCP that gives information about reaction selectivity. Moreover, as [¹¹C]CO is a radioactive gas, the parameter TE needs to be taken into account. TE is the total amount of [¹¹C]CO trapped in the reaction solution that is converted to non-volatile entities at the end of the reaction. RCY was calculated from the RCP and TE (*i.e.* $RCY = RCP \times TE$).

4.3 | Application to GE Tracerlab FX-C

A Tracerlab FX-C system (GE PETtrace, Uppsala, Sweden) was used for semi-preparative HPLC purification, in parallel with the [¹¹C]CO-synthesizer prototype (General Electrics Medical Systems, Uppsala, Sweden) to produce ^{[11}C]7. In short, ¹¹C-carbon monoxide was transferred from the $[^{11}C]$ CO-system to the stainless-steel loop in the Tracerlab FX-C system where the reaction was taking place. The crude product was obtained in the HPLC loop and then purified using a semi-preparative HPLC column (ACE C-18, 5 μ m, 10 × 250 mm; Advanced Chromatography Technologies Ltd; Aberdeen, UK) eluted with an isocratic mobile phase consisting of 30% MeCN in HCO₂NH₄ (0.1M). The eluate was monitored for absorbance ($\lambda = 254$ nm) and for radioactivity. [¹¹C]7 ($t_R = 8$ – 10 min) was collected and diluted with water (~50 mL) and then concentrated on a C-18 SepPak (Waters, Sweden). The SepPak was then washed with water (~8 mL) prior to elution with ethanol (99%, 1.5 mL) into saline (10 mL). The formulation was finally filtered through a yellow sterile filter (0.22 µm, Millipore, Millex®GV) to yield the final product in a sterile injection vial.

4.4 | Synthesis of [¹¹C]*N*,*N*benzylbenzamide

An oven-dried disposable 4 mL vial was equipped with a screw thread cap, a rubber septum and cooled under

Nitrogen (N₂) atmosphere. Pd₂[π -cinnamyl]Cl₂ (2.3 mg; 1eq), xantphos (5.0 mg; 2 eq), iodobenzene (1.4 μ L, 1.42 eq) were dissolved in anhydrous THF (700 μ L) and the resulting mixture was flushed with N₂ until the THF was fully evaporated (20 min). 1,4-Dioxane (150 μ L) and Benzylamine (10 μ L) were added and the reaction mixture was introduced into the HPLC loop approximately 2 min prior to start of synthesis. The resulting mixture was allowed to react for 5 min at r.t.

4.5 | Synthesis of [¹¹C]phthalide

Pd₂[π -cinnamyl]Cl₂ (6.7 mg; 3 eq), xantphos (7.5 mg; 3 eq) and iodobenzyl alcohol (3.0 μ L, 3 eq) were dissolved in anhydrous THF (700 μ L) kept at r.t. for 15 min and then heated at 75°C during 5 min. THF (150 μ L) was added and the resulting mixture was introduced into the HPLC loop approximately 2 min prior to start of synthesis. The resulting mixture was allowed to react for 5 min at 75°C.

4.6 | Synthesis of [¹¹C]methyl benzoate

Pd₂[π -cinnamyl]Cl₂ (2.3 mg; 1eq), xantphos (5.0 mg; 2eq) and iodobenzene (2.2 μ L, 2.9 eq) were dissolved in anhydrous THF (700 μ L) and the resulting mixture was flushed with N₂ until the THF was fully evaporated (20 min). THF (150 μ L) and a solution of lithium methoxide in MeOH (1M, 40 μ L) were added and the reaction mixture was introduced into the HPLC loop approximately 2 min prior to start of synthesis. The resulting mixture was allowed to react for 5 min at 120°C.

4.7 | Synthesis of [¹¹C]benzoic acid

Pd₂[π -cinnamyl]Cl₂ (2.2 mg), xantphos (5.0 mg) and iodobenzene (1.4 μ L) were dissolved in anhydrous THF (700 μ L) and the resulting mixture was flushed with N₂ until the THF was fully evaporated (20 min). 1,4-Dioxane (150 μ L) and a solution of NaOH (0.35 M, 3.5 μ L) were added and the reaction mixture was introduced into the HPLC loop approximately 2 min prior to start of synthesis. [¹¹C]CO was swept at r.t to the loop in which the coupling reagents were already added. The resulting mixture was allowed to react for 5 min at r.t.

4.8 | Synthesis of [¹¹C]AZ13198083

Pd₂[π -cinnamyl]Cl₂ (2.2 mg; 1 eq), xantphos (5.0 mg; 2 eq), ((2S)-2-(4-bromophenyl)cyclopropyl)(4-cyclobutyl-piperazin-1-yl)methanone (3.3 μ L) were dissolved in

106 WILEY Radiopharmaceuticals

anhydrous THF (700 μ L) and the resulting mixture was flushed with N₂ until the THF was fully evaporated (20 min). A solution of ethylamine in THF (2M, 600 μ L) was added and the reaction mixture was introduced into the HPLC loop approximately 2 min prior to start of synthesis. The resulting mixture was allowed to react for 5 min at 100°C.

4.9 | Synthesis of [¹¹C]olaparib

Pd (dba)₂ (11.5 mg), P^tBu₃ (4.9 μ L) and 4-(4-fluoro-3iodobenzyl)phthalazin-1(2H)-one (7.6 mg) were dissolved in anhydrous THF (700 μ L) and the resulting mixture was flushed with N₂ until the THF was fully evaporated (20 min). THF (150 μ L) and cyclopropyl (piperazin-1-yl)methanone (10.1 μ L) were added and the reaction mixture was introduced into the HPLC loop approximately 2 min prior to start of synthesis. The resulting mixture was allowed to react for 5 min at 100°C.

4.10 | Synthesis of [¹¹C]raclopride

Pd₂[π -cinnamyl]Cl₂ (6.4 mg; 1 eq), xantphos (7.1 mg; 1eq) and 4,6-dichloro-2-iodo-3-methoxyphenol (5.9 mg, 1.5 eq) were dissolved in anhydrous THF (1 mL) and the resulting mixture was flushed with N₂ until the THF was fully evaporated (20 min). THF (150 μ L) and (S)-(-)-2-Aminomethyl-1-ethylpyrrolidine (30 μ L) were added and the reaction mixture was introduced into the HPLC loop approximately 2 min prior to start of synthesis. The resulting mixture was allowed to react for 5 min at 75°C.

4.11 | Synthesis of [¹¹C]FLB457

Pd₂[π -cinnamyl]Cl₂ (2.2 mg; 1 eq), Xantphos (5.0 mg; 2 eq), 5-bromo-1-iodo-2,3-dimethoxybenzene (5.1 mg) were dissolved in anhydrous THF (700 μ L) and the resulting mixture was flushed with N₂ until the THF was fully evaporated (20 min). 1,4-Dioxane (150 μ L) and (S)-(-)-2-Aminomethyl-1-ethylpyrrolidine (27 μ L) were added and the reaction mixture was introduced into the HPLC loop approximately 2 min prior to start of synthesis. The resulting mixture was allowed to react for 5 min at 75°C.

ACKNOWLEDGEMENTS

This project has received funding from the European Union's Horizon 2020 research and innovation program

under the Marie Sklodowska-Curie grant agreement 675071.

The authors would like to thank members of PET group at Karolinska Institutet.

ORCID

Mélodie Ferrat D https://orcid.org/0000-0001-7004-3565 Kenneth Dahl D https://orcid.org/0000-0003-2948-2042

REFERENCES

- 1. Långström B, Lundqvist H. The preparation of ¹¹C-methyl iodide and its use in the synthesis of ¹¹C-methyl-L-methionine. *Int J Appl Radiat Isot.* 1976;27(7):357-363.
- Larsen P, Ulin J, Dahlström K, Jensen M. Synthesis of [¹¹C] Iodomethane by iodination of [¹¹C]methane. *Appl Radiat Isot*. 1997;48(2):153-157.
- Långström B, Itsenko O, Rahman O. [¹¹C]Carbon monoxide, a versatile and useful precursor in labelling chemistry for PETligand development. *J Label Compd Radiopharm.* 2007;50(9-10):794-810.
- Lidström P, Kihlberg T, Långström B. [¹¹C]Carbon monoxide in the palladium-mediated synthesis of ¹¹C-labelled ketones. J Chem Soc Perkin Trans. 1997;1, 18:2701-2706.
- Kihlberg T, Långströms B. Biologically active ¹¹C-labeled amides using palladium-mediated reactions with aryl halides and [¹¹C] carbon monoxide. *J Org Chem.* 1999;64(25):9201-9205.
- Miller PW, Long NJ, De Mello AJ, et al. Rapid multiphase carbonylation reactions by using a microtube reactor: applications in positron emission tomography ¹¹C-radiolabeling. *Angew Chem Int Ed.* 2007;46(16):2875-2878.
- Audrain H, Martarello L, Gee A, Bender D. Utilisation of ¹¹Clabelled boron carbonyl complexes in palladium carbonylation reaction. *Chem Commun.* 2004;5:558-559.
- Kealey S, Miller PW, Long NJ, Plisson C, Martarello L, Gee AD. Copper(I) scorpionate complexes and their application in palladium-mediated [¹¹C]carbonylation reactions. *Chem Commun.* 2009;25:3696-3698.
- Eriksson J, Hoek JVD, Windhorst AD. Transition metal mediated synthesis using [¹¹C]CO at low pressure – a simplified method for ¹¹C-carbonylation. J Label Compd Radiopharm. 2012;55(6):223-228.
- Lindhe Ö, Almqvist P, Kågedal M, et al. Autoradiographic mapping of 5-HT(1B/1D) binding sites in the rhesus monkey brain using [carbonyl-¹¹C]zolmitriptan. *Int J Mol Imaging.* 2011;2011 (2011):6.
- Wall A, Kågedal M, Bergström M, et al. Distribution of zolmitriptan into the CNS in healthy volunteers. *Drugs in R&D*. 2005;6(3):139-147.
- Lu S, Hong J, Itoh T, et al. [carbonyl-¹¹C]Benzyl acetate: Automated radiosynthesis via Pd-mediated [¹¹C]carbon monoxide chemistry and PET measurement of brain uptake in monkey. *J Label Compd Radiopharm.* 2010;53(8):548-551.
- Takashima-Hirano M, Ishii H, Suzuki M. Synthesis of [¹¹C] Am80 via novel Pd(0)-mediated rapid [¹¹C]carbonylation using

arylboronate and [¹¹C]carbon monoxide. *ACS Med Chem Lett*. 2012;3(10):804-807.

- 14. Rahman O, Takano A, Amini N, et al. Synthesis of ([¹¹C]carbonyl)raclopride and a comparison with ([¹¹C]methyl) raclopride in a monkey PET study. *Nucl Med Biol.* 2015;42 (11):893-898.
- Dahl K, Nakao R, Amini N, et al. Development of [Carbonyl-¹¹⁻ C]AZ13198083, a novel histamine type-3 receptor radioligand with favorable kinetics. ACS Chem Neurosci. 2018;9(5):906-911.
- 16. McCarron JA, Turton DR, Pike VW, Poole K.G. Remotely-controlled production of the 5-HT1A receptor radioligand, [carbonyl-¹¹C]WAY-100635, via ¹¹C-carboxylation of an immobilized Grignard reagent. J Label Compd Radiopharm 1996;38(10):941-953.
- Wilson AA, Garcia A, Jin L, Houle S. Radiotracer synthesis from [C-11]-iodomethane: A remarkably simple captive solvent method. *Nucl Med Biol.* 2000;27(6):529-532.
- Dahl K, Schou M, Amini N, Halldin C. Palladium-mediated [¹¹C]carbonylation at atmospheric pressure: A general method using xantphos as supporting ligand. *Eur J Org Chem.* 2013;7:1228-1231.

- 19. Martinelli JR, Watson DA, Freckmann DMM, Barder TE, Buchwald SL. Palladium-catalyzed carbonylation reactions of aryl bromides at atmospheric pressure: A general system based on xantphos. *J Org Chem.* 2008;73(18):7102-7107.
- Dahl K, Schou M, Ulin J, Sjöberg CO, Farde L, Halldin C. ¹¹Ccarbonylation reactions using gas–liquid segmented microfluidics. *RSC Adv.* 2015;5(108):88886-88889.
- Andersen TL, Friis SD, Audrain H, Nordeman P, Antoni G, Skydstrup T. Efficient ¹¹C-carbonylation of isolated aryl palladium complexes for PET: Application to challenging radiopharmaceutical synthesis. *J Am Chem Soc.* 2015;137(4): 1548-1555.

How to cite this article: Ferrat M, Dahl K, Halldin C, Schou M. "In-loop" carbonylation—A simplified method for carbon-11 labelling of drugs and radioligands. *J Label Compd Radiopharm*. 2020;63:100–107. <u>https://doi.org/10.1002/jlcr.3805</u>